Navigation Links
Study Highlights CyberKnife SBRT Benefits for Treatment of Central Lung Tumors
Date:1/26/2012

SUNNYVALE, Calif., Jan. 26, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today publication of a study demonstrating the benefits of the CyberKnife® Robotic Radiosurgery System in treating central lung tumors. Historically, the treatment of central lung tumors using gantry based Stereotactic Body Radiotherapy (SBRT) has been challenging and required a great deal of accuracy to avoid risks of damaging critical structures, such as the airway, esophagus and heart that can result in serious complications including death, leaving patients with fewer, less effective and sometimes only palliative options. This study, published in the January 2012 online issue of Radiotherapy & Oncology (commonly known as the Green Journal), demonstrated that the CyberKnife System, which leverages the Synchrony® Respiratory Tracking System and Lung Optimized Treatment to non-invasively track and correct for respiratory motion, allows clinicians to deliver lung SBRT to patients with central lung lesions with minimal toxicity, sparing surrounding healthy tissue, such as the esophagus, trachea and heart while also providing high levels of tumor control.

The study, "Outcome of Four-Dimensional Stereotactic Radiotherapy for Centrally Located Lung Tumors," reports on 56 patients (39 with primary lung cancer and 17 with metastatic tumors) treated with CyberKnife lung SBRT who were ineligible for surgery or chemotherapy, refused surgery or chemotherapy, or had an inoperable tumor. Local tumor control was 91 percent for the entire group at one year and 76 percent for the entire group at two years. The analysis of toxicity rates demonstrated that there were no serious complications reporting no acute grade three esophagitis, no grade four (life threa
'/>"/>

SOURCE Accuray Incorporated
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... June 19, 2013 Today MedeAnalytics, a ... the next-generation of its Employer Group and ... plans to provide their employer groups an intuitive ... medical and prescription drug claims, network utilization, and ... http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer Group and ...
(Date:6/19/2013)... FRANCISCO , June 19, 2013  It may seem ... possible cure for breast cancer. But these were two of ... Society,s 95 th Annual Meeting & Expo that just ... some are saying this focus by some of the top ... our culture,s obsession with new research that can not only ...
(Date:6/18/2013)...  Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT ), ... and commercialization of novel bile acid therapeutics to treat ... underwritten public offering of 1,730,000 shares of its common ... share.  In addition, Intercept has granted the underwriters a ... shares of common stock. All of the ...
Breaking Medicine Technology:MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 3"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 4Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... Aug. 27 Pharmacopeia,(Nasdaq: PCOP ), ... of novel,small molecule therapeutics, announced today that ... Special Program for Research and Training,in Tropical ... novel antimalarial,agents. Pharmacopeia will receive funding to ...
... have started a phase IIa clinical trial designed to ... C viral infection, one,of the toughest infectious diseases in ... which works as a,regulator of the body,s immune response, ... hepatitis C viral infection. "The drugs currently in ...
Cached Medicine Technology:Drug in New Hepatitis C Clinical Trial 2
(Date:6/19/2013)... are increasingly common on college campuses, but are ... up"? A new study by researchers with The ... published online by the Archives of Sexual ... behaviors associated with sexual hookups, particularly among first-year ... negative emotional and physical health outcomes as a ...
(Date:6/19/2013)... 19, 2013 The Movement ... neurosurgeons, psychiatrists and urologists with specialists in physical ... works with patients and their family members to ... of life. Patients also have the opportunity to ... research. , “Movement disorders can be relentlessly progressive ...
(Date:6/19/2013)... Could drugs that block the body,s system for repairing ... to health? As unlikely as it may seem, those ... and breast cancers driven by a mutation in BRCA, ... revealed she carries the mutation. The compounds, termed PARP ... the current edition of Chemical & Engineering News ...
(Date:6/19/2013)... Research Triangle Park, NC (PRWEB) June 19, 2013 ... Entegrion , Inc., announced organizational changes to ... Chairman John B. Mowell said, “To support the ... of Directors has made changes to the Company’s ... advisors.” , The Company announced that ...
(Date:6/19/2013)... Moffitt Cancer Center and colleagues at Louisiana State University ... that require immediate therapy. It relies on understanding the ... is to better predict a prostate cancer,s aggressiveness to ... published in the online journal PLOS ONE ... accounts for 20 percent of all cancers and 9 ...
Breaking Medicine News(10 mins):Health News:Why are some college students more likely to 'hook up'? 2Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 3Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2
... University Melvin and Bren Simon Cancer Center will ... health care solutions. WellPoint announced plans in ... to help improve patient care and support physicians ... personalized treatment decisions possible. It is estimated that ...
... the screw. That,s just a part of life for people, ... osteogenesis, a method to correct bone deformities that leave one ... University undergraduates has invented a device they hope will make ... Hospital for Children in Houston, the students came up with ...
... April 23 (HealthDay News) -- It goes without saying that ... they can also be very expensive, an expert warns. ... a person bitten by a venomous snake, said Jill Heatley, ... in College Station. The total cost includes hospitalization, which ...
... SAGE Launch Clinical Psychological Science ,Association for Psychological ... Angeles, CA (April 23, 2012) The Association for ... Clinical Psychological Science , a new peer-reviewed journal focused ... venue for cutting-edge research across a wide range of ...
... and American Associations for Dental Research have published ... articles, titled "Hypoplasia-Associated Severe Early Childhood Caries ... York University College of Dentistry) and "Deciduous Molar ... Elfrink, Academic Centre for Dentistry, Amsterdam) discuss the ...
... Guy, M.D., professor of ophthalmology at Bascom Palmer Eye ... Medicine, has pioneered a novel technological treatment for Leber ... causes rapid, permanent, and bilateral loss of vision in ... Genetic mutations in the mitochondria (part of the ...
Cached Medicine News:Health News:IU Simon Cancer Center joins WellPoint in developing health care solutions 2Health News:IU Simon Cancer Center joins WellPoint in developing health care solutions 3Health News:Rice University student engineers automate limb lengthening for kids 2Health News:Rice University student engineers automate limb lengthening for kids 3Health News:Cost of Snakebite Therapy May Squeeze Victims' Wallets 2Health News:Association for Psychological Science, SAGE launch Clinical Psychological Science 2Health News:IADR/AADR publish studies on severe early childhood caries - proposes new classification 2Health News:IADR/AADR publish studies on severe early childhood caries - proposes new classification 3Health News:Bascom Palmer Eye Institute announces breakthrough for degenerative vision disorder 2
... Wampole Laboratories offers a comprehensive line of ... serum and urine in convenient one-step stick ... 2 testing options. Clearview Easy HCG is ... convenient stick format. Clearview HCG II ...
The BioCheck hCG ELISA is intended for the quantitative determination of human chorionic gonadotropin (hCG) concentration in human serum. The assay is for use in the early diagnosis of pregnancy in a...
... preparation of whole blood is mixed continuously ... cation-exchange resin. During this time, HbAo binds ... a filter separator is used to remove ... contains glycohemoglobin. The percent glycohemoglobin is determined ...
The BioCheck Ferritin ELISA is intended for the quantitative determination of ferritin in human serum. This assay is to be used in the diagnosis of diseases affecting iron metabolism....
Medicine Products: